<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728012</url>
  </required_header>
  <id_info>
    <org_study_id>REK2010/2926</org_study_id>
    <nct_id>NCT01728012</nct_id>
  </id_info>
  <brief_title>Long-term Cardiovascular Risk Following Successful Renal Transplantation</brief_title>
  <official_title>The Prevalence of Cardiovascular Risk Factors in Patients More Than 10 Years Following Successful Renal Transplant.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <authority>Norway: Data Protection Authority</authority>
    <authority>Norway: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mineral metabolism disturbances occur early during the course of chronic kidney disease and
      eventually affect most patients. For how long such disturbances persist after a successful
      renal transplantation is mainly unknown. This study will investigate the prevalence of such
      disturbances in patients more than 10 years following a successful renal transplantation.
      The patients will be recruited from an existing registry in Norway.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Fibroblast growth factor 23 (FGF23)</measure>
    <time_frame>More than 10 years after successful renal transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the long-term effect of a successful renal transplant on this biomarker.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intact parathyroid hormone (iPTH)</measure>
    <time_frame>More than 10 years after successful renal transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the long-term effect of a successful renal transplant on this biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Klotho</measure>
    <time_frame>More than 10 years after successful renal transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the long-term effect of a successful renal transplant on this biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>More than 10 years after successful renal transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the long-term effect of a successful renal transplant on this biomarker.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>eGFR &gt;=60ml/min/1.73m2</arm_group_label>
    <description>Patients with an estimated glomerular filtration rate of &gt;=60 ml/min/1.73m2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eGFR 45-60ml/min/1.73m2</arm_group_label>
    <description>Patients with estimated glomerular filtration rate &gt;=45 ml/min/1.73m2 and &lt;60ml/min/1.73m2.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine will be collected along with the clinical observations. Serum, plasma and
      urine will be frozen for later analyses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients registered in the Norwegian Renal Registry with transplan more than 10 years ago.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Registered in the Norwegian Renal Registry

          -  Documented elevated iPTH at Tx and 10 weeks post-tx

          -  Well functioning transplant 10 years following tx

          -  Signed informed consent

        Exclusion Criteria:

          -  Lack of ability to comply with the protocol

          -  Refused written informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inger Hjørdis Bleskestad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inger Hjørdis Bleskestad, MD</last_name>
    <phone>+47 51513865</phone>
    <email>inger.hjoerdis.bleskestad@sus.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lasse Göransson, MD PhD</last_name>
    <phone>+47 51518000</phone>
    <email>lasse.goransson@sus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>NO-4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inger Hjørdis Bleskestad, MD</last_name>
      <phone>+47 51513865</phone>
      <email>inger.hjoerdis.bleskestad@sus.no</email>
    </contact>
    <contact_backup>
      <last_name>Lasse Göransson, Md PhD</last_name>
      <phone>+47 51518000</phone>
      <email>lasse.goransson@sus.no</email>
    </contact_backup>
    <investigator>
      <last_name>Inger Hjørdis Bleskestad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 11, 2012</lastchanged_date>
  <firstreceived_date>November 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Successful transplantation</keyword>
  <keyword>Long-term observation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
